tbuckley/cabot-search huggingface dataset:
P158 Cough Sound Intensity: The Development of a Novel Measure of Cough Severity: Abstract P158 Table 1
Authors: KK Lee, S Matos, K Ward, E Raywood, DH Evans, J Moxham, GF Rafferty, SS Birring
Journal: Thorax (2012)

<h3>Introduction and Objectives</h3> Cough sound analysis is currently used for the assessment of cough frequency; it is not known if it could be used to assess cough intensity. We investigated the optimal Cough Sound Intensity (CSI) measure by validating it against peak cough flow rate (PCFR). <h3>Methods</h3> 17 (11 female) patients with stable chronic cough and 15 (8 female) healthy subjects underwent simultaneous measurements of peak cough flow rate and cough sound during voluntary coughs using 2 types of microphones. Subjects were asked to cough voluntarily 10 times at 5 incremental thoracic pressures as measured by an oesophageal balloon catheter. Visual feedback was given to patients. A range of CSI parameters were determined from the cough sound signal. CSI was calculated for the actual cough sound duration and also for a constant duration (time constant) to assess the potential for automation. The repeatability of CSI and the effect of microphone position were assessed. For each subject, PCFRs and CSI data were normalised to values obtained during maximum voluntary cough (MVC). <h3>Results</h3> The correlation between the optimal CSI and peak cough flow rate was best for the free-field microphone; median (IQR) correlation coefficient 0.88 (0.79–0.92) (Table 1). The median correlation for all cough sound intensity remained strong for males (r=0.90–0.91), females (r=0.79–0.84), patients with chronic cough (r=0.79–0.82) and healthy subjects (r=0.82–0.89). The intraclass correlation coefficient for repeatability was good, r=0.90, p&lt;0.01. The CSI degraded when the microphone was positioned further away from the mouth, downwards, but not in any other position. The use of a constant cough sound duration to determine CSI did not impact on the association with PCFR (Table 1). <h3>Conclusion</h3> Cough sound intensity correlates strongly with PCFR in voluntary cough and is a repeatable measure. The microphone position needs to be standardised as in this study. Further work is needed to automate the analysis of CSI; our preliminary findings suggest this is possible. The CSI has the potential to be developed into a non-invasive, ambulatory outcome measure of cough severity.
S5 Molecular Immunodiagnosis of TB Infection: A Pilot Study
Authors: DW Connell, A-K Reuschl, C Wenden, M Witkowski, OM Kon, P Klenerman, A Lalvani
Journal: Thorax (2012)

<h3>Introduction</h3> Current interferon-gamma (IFN-γ) release assays (IGRAs) are not sufficiently sensitive to be used as a “rule-out” test for tuberculosis (TB). Antigen-specific gene expression of chemokines downstream of, and amplified by, IFN-γ might demonstrate such sensitivity, and can be performed with very small volumes of blood.<sup>1</sup> Here we assess the performance and sensitivity of two IFN-γ-dependent gene expression platforms in the peripheral blood mononuclear cells of individuals with and without TB. <h3>Methods</h3> 23 individuals with active TB, 12 individuals with latent TB infection (LTBI), and 18 controls had simultaneous IFN-γ ELISpot assays and qRTPCR of CXCL-9 and CXCL-10, following stimulation with the immunodominant antigens ESAT-6, CFP-10 and EspC (6 gene expression assays in total). Test performances of the 6 gene expression assays were compared to the ELISpot. <h3>Results</h3> Gene expression of CXCL-9 and CXCL-10 was antigen specific, correlating well with each other and with the IFN-γ ELISpot (Spearman Rank Correlations ranging from r=0.648 to 0.74). Gene expression of either was not significantly different between those with active TB and LTBI. Receiver-operating characteristic curves indicated good test performances for all the gene expression assays (AUC ranging from 0.918 to 0.959) and agreements between the ELISpot and gene expression platforms was good (κ statistic ranging from 0.403–0.496). After constructing cut-offs for sensitivity for individual antigens, with cut-offs for specificity matching or exceeding that of the IFN-γ ELISpot, the sensitivity of TB diagnosis with gene expression was superior to ELISpot in 5 out of the 6 assays, although these differences were not statistically significant. Sensitivity was equivalent when antigens were combined, as in the commercially available T-Spot<sup>®</sup>.<i>TB.</i> <h3>Conclusions</h3> These pilot data indicate that gene expression of IFN-γ-dependent cytokines is a robust, sensitive and specific method of TB diagnosis, and carries potential to be a more sensitive platform that the current gold standard – IFN-γ ELISpot. Larger studies with appropriate power are now required in similar populations to investigate this approach definitively. <h3>References</h3> Kasprowicz VO, Mitchell JE, Chetty S, Govender P et al. A molecular assay for sensitive detection of pathogen-specific T-cells. PLoS One. 2011; 6(8):e20606. Epub 2011 Aug 11.
P18.08 * A MULTICENTRIC, OBSERVATIONAL, NON INTERVENTIONAL STUDY OF EFFICACY AND SAFETY OF LACOSAMIDE FOR THE TREATMENT OF EPILEPTIC SEIZURES IN PATIENTS WITH BRAIN TUMORS
Authors: J. Pardo-Moreno, J. Sepulveda, A. Conde-Moreno, M. Baron, G. Reynes, A. Belenguer
Journal: Neuro-Oncology (2014)

INTRODUCTION: Epileptic seizures are common in oncologic patients. Seizures could be the initial symptom of a brain tumor in 20-40% of the cases and 40% of the patients with brain tumors will have a seizure throught the diseqse. Management of these complications is crucial in the treatment of brain tumors. The ideal antiepileptic drug (AED) would be that one which could ensure a high and proved efficacy, wide security, low interactions, easy and quick to titrate and available in i.v. formulation. Until today there is a scarce number of publications on the use of lacosamide (LCM) in patients with btain tumors, although there is some experience in routine clinical practice that has previously shown a very promising profile of efficacy and safety. This study tries to compile some of these experiences in Spain. OBJECTIVES: To evaluate the efficacy of LCM in the management of seizures in patients with brain tumors. Secondary objectives were the evaluation of safety and tolerability of LCM . DESIGN: Multicentric, observational, non-interventional retrospective study. Patients who suffered at least 1 convulsive episode and at least treated with 1 dose of LCM were recruited. RESULTS: 37 patients with brain tumor suffering seizures were recruited in 6 centers all over the country, and 24 of them (64.9%) could be followed-up until the end of the study (after 6 months). Of these 37 patients, 26 (70%) were male, the age was 54.14 ± 14 years. 28 patients had one lesion and 9 had several lesions, 7 of them were metastatic. The average of total number of seizures from the onset of LCM treatment to the last visit performed shows a statistically significant change from the initiation of LCM treatment, showing a reduction of -16.8 ± 41'7 seizures. (p <000.1) The reason for withdrawing from the study was death by cancer in 7 of all the 37 initially included (53.85%), being a lack of LCM efficacy in 2 patients. A total of 12 more patients needed a LCM modification of treatment, 9 due to lack of efficacy, 3 due to adverse events. CONCLUSIONS: In a retrospective, non-interventional study with brain tumor patients, LCM has shown to be effective and safe in the management of seizures in neurooncological patients.
EVALUATION OF 111IN ANTIMYOSIN (Fab FRAGMENT) FOR DETECTING REJECTION OF TRANSPLANTED HEARTS.
Authors: George Segall
Journal: Clinical Nuclear Medicine (1986)

William Frist, I. Ross McDougall, Tsunehiro Yasuda, Ban An Khaw, H. William Strauss, Herman Gold, Marshall Jacobs, G. William Dec, Igor Palacios, Edward Stinson, Philip Oyer, Edgar Haber; Stanford University Medical Center, Stanford, CA, and Massachusetts General Hospital, Boston, MA.
Hydrocele Mimicking Testicular Torsion on Radionuclide and Ultrasound Studies
Authors: NAZLI ERBAY, SUZANNE L. BROWN, RICHARD P. SPENCER
Journal: Clinical Nuclear Medicine (1997)

A 24-year-old man with a swollen right testis was noted, by ultrasound (US), to have a hydrocele on that side, and homogenous echogenicity. Clear demonstration of blood flow was not possible. A Tc-99m RBC radionuclide study also did not show perfusion of the right testis. At operation, massive hydrocele was noted to have reduced vascular pulsations to the testis. Reported difficulties with diagnosing testicular torsion with use of US or radionulcide angiograms were reviewed.
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Authors: F B Karassa, D A Isenberg
Journal: New England Journal of Medicine (2001)

BackgroundThe combination of cyclophospha- mide and prednisolone is effective for the treatment of severe lupus nephritis but has serious adverse effects.Whether mycophenolate mofetil can be substituted for cyclophosphamide is not known. MethodsIn 42 patients with diffuse proliferative lu- pus nephritis we compared the efficacy and side effects of a regimen of prednisolone and mycophenolate mofetil given for 12 months with those of a regimen of prednisolone and cyclophosphamide given for 6 months, followed by prednisolone and azathioprine for 6 months.Complete remission was defined as a value for urinary protein excretion that was less than 0.3 g per 24 hours, with normal urinary sediment, a normal serum albumin concentration, and values for serum creatinine and creatinine clearance that were no more than 15 percent above the base-line values.Partial remission was defined as a value for urinary protein excretion that was between 0.3 and 2.9 g per 24 hours, with a serum albumin concentration of at least 3.0 g per deciliter.
EXERTIONAL CHANGES IN CIRCULATING CARDIAC NATRIURETIC PEPTIDE AND LEFT VENTRICULAR FUNCTION IN UNTRAINED HEALTHY YOUNG SUBJECTS
Authors: Hack-Lyoung Kim, Jae-Bin Seo, Woo Young Jung, Sue Shin, Sang Hyun Kim, Jong Hyun Yoon, Myung-A Kim, Joo-Hee Zo
Journal: Journal of the American College of Cardiology (2015)
P5-18-11: Incidence of Chemotherapy Dose Reductions and Dose Delays, and Reduced Chemotherapy Dose Intensity in Early Stage Breast Cancer.
Authors: D Weycker, J Edelsberg, A Kartashov, R Barron, G Lyman
Journal: Cancer Research (2011)

Abstract Background: Chemotherapy is widely used to treat early stage breast cancer (ESBC). Dose reductions and dose delays–e.g., due to advanced age or severe/febrile neutropenia–are generally believed to increase risk of disease progression and reduce survival. Little is known about incidence of chemotherapy dose reductions and dose delays among women with ESBC in clinical practice. Methods: This study employed a retrospective cohort design and electronic medical records from over 60 community oncology clinics in more than 20 states (2004-2010). Study population included adult women who received myelosuppressive chemotherapy for ESBC (stages I-IIIA). For each such woman, each unique cycle of chemotherapy within their first observed course was identified. Incidences of chemotherapy dose delays (≥7 days for any drug in ≥1 cycles), chemotherapy dose reductions (≥15% for any drug in ≥1 cycles), and low relative chemotherapy dose intensity (&amp;lt;85% over the course) – relative to physician-reported planned chemotherapy administration – were descriptively analyzed for the seven most frequently observed regimens among subjects. Results: 2,350 women received seven most frequently observed regimens (80% of study population); mean age – across regimens – ranged from 51–56 years, and 31–94% received primary prophylaxis against severe/febrile neutropenia with a colony-stimulating factor. Incidence of dose reductions ranged from 17–48%, and dose delays, from 24–45%. Overall mean relative dose intensity (RDI) ranged from 80%-99%, and 17–50% of subjects received RDI &amp;lt;85%; mean RDI among those with low RDI ranged from 40%-67%. Discussion: Chemotherapy dose delays and dose reductions are common in ESBC, among those receiving dose-dense as well as conventional regimens. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-18-11.
IMPACT OF BASELINE PULMONARY PRESSURES ON LONG-TERM OUTCOME IN MYXOMATOUS MITRAL REGURGITATION: THRESHOLD OR PROGRESSIVE EFFECT?
Authors: Harsh Patel, Krishna Patel, Amgad Mentias, A. Gillinov, Richard Grimm, L. Leonardo Rodriguez, Tomislav Mihaljevic, Joseph Sabik, Brian Griffin, Milind Desai
Journal: Journal of the American College of Cardiology (2015)
PHARMACOLOGICAL INHIBITION OF GALECTIN-3 AND ALDOSTERONE PATHWAYS PREVENTS ISOPROTERENOL-INDUCED LEFT VENTRICULAR DYSFUNCTION AND FIBROSIS IN MICE
Authors: Giuseppe Vergaro, Mathilde Prud’homme, Regine Merval, Claudio Passino, Michele Emdin, Jane-Lise Samuel, Alain Cohen-Solal, Claude Delcayre
Journal: Journal of the American College of Cardiology (2015)
Abstract 831: Chemopreventive effects of selective estrogen receptor modulator (SERM) raloxifene on intestinal neoplasia of APCMin/+ mice
Authors: Naveena B. Janakiram, Altaf Mohammed, Li Qian, Madka Venkateshwar, Manasa P. Reddy, Vernon E. Steele, Chinthalapally V. Rao
Journal: Cancer Research (2011)

Abstract Estrogen receptor β (ER-β) has been implicated in several neoplastic diseases. Previously we have shown that ER-β is up-regulated in human and rodent colonic tumors, suggesting ER-β as a potential target for colon cancer prevention (Naveena et al., CaPR 2009). Thus, ER-β modualtors, SERMs are useful for colon cancer prevention. Hence, we tested raloxifene, an ER antagonist in APCMin/+ mice treated with azoxymethane (AOM), to enhance the colonic tumors. Six-week-old male and female APCMin/+ (9/group) were injected s.c., with AOM at 5 mg/kg BW, once a week for three weeks. APCMin/+ mice were then fed diets containing 0, 1.5, and 3.0 ppm raloxifene for 12 weeks before intestinal tumors and various markers of toxicity, cell proliferation and apoptosis were evaluated. Results suggest that dietary administration of 1.5 and 3.0 ppm raloxifene in male mice suppressed small intestinal polyp formation by 24% (p&amp;lt;0.05) and 58% (p&amp;lt;0.0001), respectively. In female mice, 1.5 and 3.0 ppm raloxifene suppressed small intestinal polyps by 58% (0&amp;lt;0.0001) and 48% (p&amp;lt;0.0001), respectively. Also, significant inhibition of colonic tumor suppression was observed in female mice fed the 1.5 and 3.0 ppm of raloxifene, whereas in male mice, only high-dose inhibited colonic tumors. Mice fed with raloxifene had &amp;gt;70% less polyps with size of &amp;gt;1-mm suggesting suppression of tumor volume/size. Also, we find that raloxifene treatment in female APCMin/+ mice showed significantly reduced serum creatine phosphokinase and cholesterol levels, and an increased alkaline phosphatase levels when compared to untreated control mice. Also, a dose-dependent increase in serum calcium was observed with raloxifene administration. Dietary raloxifene showed no liver enzyme toxicities as measured by aspartate aminotransferase levels in serum. However, raloxifene administered mice showed a modest decrease in serum glucose levels. The mRNA and protein expression levels for p21cip/waf1 were significantly higher with decreased expression of Cyclin D1 and PCNA in raloxifene treated colonic tumors and SI polyps compared to control diet fed mice tissues, suggesting estrogen's function in crypt cell proliferation. Overall, our results clearly suggest that raloxifene significantly suppresses small intestinal and colonic polyps formation by up-regulating p21cip/waf1 and has potential usefulness for human colon cancer prevention. (Supported by CN53300 and R01-94962) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 831. doi:10.1158/1538-7445.AM2011-831
1323 CONTROLLED ATTENUATION PARAMETER (CAP) FOR NON-INVASIVE ASSESSMENT OF LIVER STEATOSIS IN THE GENERAL POPULATION: CORRELATION WITH ULTRASOUND (US) AND FATTY LIVER INDEX (FLI)
Authors: S. Carvalhana, J. Leitao, A.C. Alves, M. Bourbon, H. Cortez- Pinto
Journal: Journal of Hepatology (2013)
Watermelon stomach in dengue hemorrhagic fever
Authors: W.-H. Hsu, I.-C. Wu
Journal: Endoscopy (2013)

A previously healthy 69-year-old man came to our emergency room with complaints of melena, abdominal pain, poor appetite, and general myalgia. Fever had occurred four days earlier, for which a nonsteroidal anti-inflammatory drug was prescribed. Physical examination revealed normal findings. Laboratory studies showed a white blood cell count of 11.3 × 109/L, hemoglobin 140 g/L, and thrombocytopenia with platelet count 15 × 109/L. The prothrombin time and activated partial thromboplastin times were 10.8 seconds (control: 11.0 seconds) and 36.6 seconds (control: 29.1 seconds), respectively. Elevated liver function results (aspartate aminotransferase 271 U/L, alanine aminotransferase 246 U/L) were also noted. Urgent endoscopy revealed linear strips of erythematous mucosa radiating from the pylorus to the antrum, mimicking gastric antral vascular ectasia (also called watermelon stomach; [Fig. 1]). Active oozing was seen, and endoscopic hemostasis with argon plasma coagulation was performed successfully ([Video 1]). Tracing back his history, the patient remembered having suffered mosquito bites before the fever occurred. Serology results were positive for dengue-specific IgG and IgM. Supportive care was given and the patient's platelet count recovered to 208 × 109/L 4 days later. He was then discharged without recurrent bleeding episodes. However, he refused a follow-up endoscopic exam with biopsy to confirm the finding.
FRI0516 The Largest Cohort of Children and Adolescents with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus Infection (Pandas): Preliminary Descriptive Analysis
Authors: F. Falcini, A. Meini, G. Lepri, D. Rigante, A. Ferrari, E. Casalini, M. Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> PANDAS is defined by neuropsychiatric symptoms, mainly obsessive-compulsive disorder (OCD) or tics, temporally associated with group A β-hemolytic <i>Streptococcus</i> (GAS) infections, showing acute prepubertal onset and relapsing/remitting course. <h3>Objectives</h3> To describe the clinical features of a cohort of 242 Italian pts with OCD and/or tics related to a previously confirmed GAS infection. <h3>Methods</h3> Between May 2009 and January 2015 we recruited 242 pts (185 males, 76.45%) with OCD and/or tics starting before puberty associated with a previous upper airway infection (impetigo in 2 cases). GAS infection was confirmed in all patients. Their mean age at onset was 77.64 months ±30.1 SD. <h3>Results</h3> Two hundred and twenty-three children (93.31%) were full-term born after a regular pregnancy, and 52 (37.68%) from Caesarean section (though for 4 adopted children there were no information); 101/236 (42.8%) had familiars with OCD/tics or other neurologic diseases (for 6 patients there were no familial history data). Sport activity was evaluated in only 149 out of 242 patients, and was performed by 122/149 (81.88%). Clinical signs were motor tics in 109/242 (45.04%), vocal tics in 6/242 (2.48%), motor/vocal tics in 28/242 (3.31%), motor/vocal tics and OCD in 18/242 (7.44%), OCD in 16/242 (6.61%), OCD and motor tics in 61/242 (25.21%), OCD and vocal tics in 4/242 (1.65%). At the first evaluation the mean age was 102.70 months ±35.12 SD. Brain MRI was performed resulting within normal limits in 110/242 patients. Pharyngeal swab was positive in 34/242 (14.05%). A<i>nti-streptolysin</i> O titer was &lt;250 IU in 19/242 (7.85%), 250-550 in 66/242 (27.28%), &gt;550 in 129/242 (53.31%), while in the remaining 28/242 (11.57%) this titer was in progress or not evaluated. Anti-DNase B titer was &gt;650 IU/ml in 76/242 (31.4%) and &lt;650 in 42/242 (17.36%); in the remaining 118 (48.76%) this titer was not evaluated. Anti-nuclear antibodies were studied in 142/242 patients, resulting positive in 7/142 (4.93%). All patients received benzathine benzylpenicillin; neuroleptic drugs were used in 27/242 (11.16%). Therapeutic efficacy was null in 5/242 (2.07%), &lt;25% in 7/242 (2.89%), 25-75% in 125/242 (51.65%), &gt;75% in 58/242 (23.97%), and not-valuable in 47/242 (19.42%). <h3>Conclusions</h3> Our preliminary data in the largest pediatric population with PANDAS ever studied until now show male predominance and familiar recurrence rate over 40%. Clinical onset occurs at a mean age of 8.5±2.9 years with motor tics in 45% of cases. Increased anti-DNase B titer is found in over 30% of patients. Benzathine benzylpenicillin has resulted effective in 3/4 of cases with complete or partial remission of symptoms. <h3>Disclosure of Interest</h3> None declared
Abstract P2-16-12: First-Line Bevacizumab Combined with Paclitaxel in Triple-Negative Locally Recurrent/Metastatic Breast Cancer: Subpopulation Analysis of 115 Patients Treated in Routine Oncology Practice in Germany
Authors: A Schneeweiss, FG Foerster, W Hollburg, H Tesch, P Klare, P Wuelfing, A Distelrath, C Schumacher, C-C Steffens, R Schubert, A Widing, C Kasper, M. Schmidt
Journal: Cancer Research (2010)

Abstract Background: Both progression-free survival (PFS) and response rate (RR) are significantly improved when bevacizumab (Bev) is combined with first-line chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC), as demonstrated in three randomized, phase III trials (E2100, AVADO, RIBBON-1). The benefit derived from Bev appears to be similar in triple-negative (TN) and non-TN LR/mBC according to subanalyses of the randomized trials. We conducted a subpopulation analysis of TN patients treated with first-line Bev-paclitaxel (Pac) in a large German observational study in the context of routine oncology practice. Methods: Patients with HER2-negative LR/mBC received first-line Bev-Pac according to the European label at the time of study design. Safety and efficacy data were collected for up to 1 year (or until progression, death, or Bev discontinuation if earlier). The endpoints were safety and efficacy (PFS and RR). We conducted an exploratory analysis of the subset of patients with TN disease. Results: Of the 567 patients for whom data are currently available, 115 (20%) had TN disease. Baseline characteristics and efficacy are summarized below. Overall survival data are immature and follow-up is continuing. Conclusions: In this ongoing study, first-line Bev-Pac demonstrated a 51% RR and median PFS of 7.7 months in patients with TN LR/mBC. These data are consistent with findings from retrospective analyses of randomized phase III trials and a subpopulation analysis of the ATHENA study. Prospective trials evaluating Bev combination regimens in TN breast cancer are ongoing. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-16-12.
OMEGA-3 PUFAS IMPROVED ENDOTHELIAL FUNCTION AND LEFT VENTRICLE GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH SYSTOLIC HEART FAILURE
Authors: Evangelos Oikonomou, Dimitrios Karlis, Theodoros Zografos, Gerasimos Siasos, Christina Chrysochoou, Styliani Brili, George Lazaros, Alexis Antonopoulos, Efstathios Dimitropoulos, Petros Nihoyannopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2016)